Institutional Buyers (lack of)
This comes straight from Googles AI.
Institutional ownership of Alpha Tau Medical Ltd (DRTS) remains low—hovering around 2.65% to 4.5% of total shares—because large funds typically wait for late-stage commercial de-risking, stable revenue, and broader regulatory approvals before building massive positions in clinical-stage oncology platforms.
Financial and Operational Risk Factors Pre-Revenue and Wide Losses: Alpha Tau Medical reports widening net losses driven by intensive R&D and non-cash P&L swings from warrant liability valuations, which cause risk-averse institutional managers to hesitate.
Niche Isotope Supply Chain: The company's Alpha DaRT technology relies on Radium-224, which features a very short half-life of 3.66 days. This demands strict logistics management that large institutional funds view as a complex operational hurdle.
High Insider Ownership: Insiders and key early founders hold a substantial portion of the company's equity, which leaves a tighter active free float and less accessible volume for large block-buying by funds.
Clinical Catalysts vs. Waiting for Proof Early-Stage Clinical Focus: While DRTS has posted strong trial data—such as recent combination studies with pembrolizumab showing high objective response rates—many large biotech-focused institutions prefer seeing definitive, broad FDA approvals rather than pilot or mid-stage trial readouts.
Recent Momentum: Recent strategic moves like the Tolmar partnership and pending dual-listing on the Tel Aviv Stock Exchange are slowly increasing global visibility, but institutional accumulation historically lags behind fundamental operational milestones.
Sounds about right. Basically, big money is saying not until FDA approval. Likely end of year, but the good news just keeps coming. I wouldn't be surprised if one or two jump in soon, there's alot of potential sitting on the table.